… Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, … which is related to targeted RNA editing using endogenous ADARs and is part of ProQR’s intellectual property estate …
… against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition … stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR’s intellectual …
… A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7 th Annual Genetic … am – 10:15 am EDT, and a recording of the session will be made available on the Company’s website after the conference. … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ® EONs are …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
… title: Harnessing chemical modifications to improve ADAR potency and unlock Axiomer broad applicability Presenter: Lenka van Sint Fiet, PhD, … effective strategies to increase RNA editing yields of ADARs using chemical modifications and oligonucleotide design …
… Diseases ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are …